KEYNOTE-A18 Data Support Pembrolizumab Plus Chemoradiotherapy as New SOC in High-Risk Locally Advanced Cervical Cancer
Pembrolizumab (Keytruda) combined with chemoradiotherapy and then continued as monotherapy led to statistically significant and clinically meaningful improvements in survival vs chemoradiotherapy alone in patients with newly diagnosed, previously untreated …